Literature DB >> 24345631

Acceleration time of systolic coronary flow velocity to diagnose coronary stenosis in patients with microvascular dysfunction.

Kazushi Takemoto1, Kumiko Hirata2, Nozomi Wada1, Yasutsugu Shiono1, Kenichi Komukai1, Takashi Tanimoto1, Yasushi Ino1, Hironori Kitabata1, Shigeho Takarada1, Nobuo Nakamura1, Takashi Kubo1, Atsushi Tanaka1, Toshio Imanishi1, Takashi Akasaka1.   

Abstract

BACKGROUND: The aim of this study was to test whether acceleration time of systolic coronary flow velocity could contribute to the diagnosis of coronary stenosis in patients with microvascular dysfunction, on the basis of the hypothesis that systolic coronary flow is less influenced by microvascular function because of compressed myocardium.
METHODS: Coronary flow velocity was assessed in the left anterior descending coronary artery during hyperemia with intravenous adenosine by echocardiography in 502 patients who were scheduled for coronary angiography because of coronary artery disease and significant valvular disease. Coronary flow velocity reserve (CFVR) and the percentage acceleration time (%AT), as the percentage of the time from the beginning to the peak of systolic coronary flow over systolic time during hyperemia, were calculated. The diagnostic ability of CFVR and %AT for angiographic coronary artery stenosis was then analyzed. As invasive substudies, fractional flow reserve and %AT by a dual-sensor (pressure and Doppler velocity) guidewire were measured simultaneously with %AT on transthoracic echocardiography (n = 14).
RESULTS: Patients with coronary stenosis had significantly lower CFVR (1.7 ± 0.4) and greater %AT (65 ± 9%) compared with those without stenosis (2.6 ± 0.6 and 50 ± 13%, respectively). Percentage acceleration time by Doppler echocardiography was in good agreement with %AT (r = 0.98) and fractional flow reserve (r = 0.74) invasively measured by dual-sensor guidewire. Cutoff values of CFVR and %AT were determined as 2.0 and 60% in receiver operating characteristic curve analysis. The sensitivity, specificity, and accuracy of CFVR to detect coronary stenosis were 71.1%, 77.3%, and 75.4%, while those of %AT were 83.4%, 71.8%, and 75.4%, respectively. In addition, %AT provided high accuracy to detect coronary stenosis, especially in patients with previous myocardial infarctions, valvular disease, and left ventricular hypertrophy (81.1%, 84.1%, and 73.4%, respectively).
CONCLUSIONS: The %AT of systolic coronary flow velocity is a promising marker to diagnose coronary stenosis in patients with microvascular dysfunction.
Copyright © 2014 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  %AT; %DS; AS; AUC; Aortic stenosis; Area under the curve; CFVR; Coronary flow; Coronary flow velocity reserve; Echocardiography; FFR; Fractional flow reserve; LV; LVEF; LVH; Left ventricular; Left ventricular ejection fraction; Left ventricular hypertrophy; MI; Myocardial infarction; Percentage acceleration time; Percentage diameter stenosis; ROC; Receiver operating characteristic

Mesh:

Substances:

Year:  2013        PMID: 24345631     DOI: 10.1016/j.echo.2013.10.013

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  3 in total

1.  Color Doppler Ultrasonography for the Evaluation of Subclavian Artery Stenosis.

Authors:  Jie Zhang; Lijuan Wang; Ying Chen; Sibo Wang; Yingqi Xing; Li Cui
Journal:  Front Neurol       Date:  2022-02-17       Impact factor: 4.003

Review 2.  Coronary Microcirculation in Aortic Stenosis: Pathophysiology, Invasive Assessment, and Future Directions.

Authors:  Jo M Zelis; Pim A L Tonino; Nico H J Pijls; Bernard De Bruyne; Richard L Kirkeeide; K Lance Gould; Nils P Johnson
Journal:  J Interv Cardiol       Date:  2020-07-22       Impact factor: 2.279

3.  Effect of Erythropoietin Administration on Myocardial Viability and Coronary Microvascular Dysfunction in Anterior Acute Myocardial Infarction: Randomized Controlled Trial in the Japanese Population.

Authors:  Makoto Orii; Kumiko Hirata; Kazushi Takemoto; Takashi Akasaka
Journal:  Cardiol Ther       Date:  2018-10-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.